Neuromuscular Blocking Agents Anaphylaxis Clinical Trial
Official title:
Anaphylaxis to Neuromuscular Blocking Agents and Pholcodine Exposure. Case-control Study
The main objective of this study is to compare pholcodine exposure in patients having
presented with a perianaesthetic anaphylactic reaction to a NMBA (cases) to pholcodine
exposure in matched anaesthetised patients with injection of NMBA, who did not present with
an anaphylactic reaction (controls).
The secondary objectives of the study are:
- To compare anti-pholcodine IgE, anti-ammonium IV IgE and total IgE levels between the
case and control groups.
- To study the concordance between exposure to pholcodine in cases and controls, by means
of a patient self-questionnaire on the one hand and, on the other hand, by a
computerized drug history, supplemented where relevant by the drug master file.
- To study the impact of taking 1, 2 or 3 sources in account for pholcodine exposition.
- To study the association between exposure to pholcodine and the presence/levels of
pholcodine-specific IgE, reflecting sensitisation to pholcodine.
- To study NMBA and pholcodine cross-sensitisation by testing skin reactions to pholcodine
in case patients allergic to (at least) one NMBA.
n/a